相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo
Sebastian Zundler et al.
GUT (2017)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Long-term Efficacy of Vedolizumab for Crohn's Disease
Severine Vermeire et al.
JOURNAL OF CROHNS & COLITIS (2017)
Long-term Efficacy of Vedolizumab for Ulcerative Colitis
Edward V. Loftus et al.
JOURNAL OF CROHNS & COLITIS (2017)
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
Amy Lightner et al.
JOURNAL OF CROHNS & COLITIS (2017)
αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+T Lymphocytes in Ulcerative Colitis
Christopher A. Lamb et al.
JOURNAL OF CROHNS & COLITIS (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo
Sebastian Zundler et al.
INFLAMMATORY BOWEL DISEASES (2017)
Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases
Sebastian Zundler et al.
INFLAMMATORY BOWEL DISEASES (2017)
P617 Extraintestinal autoimmune phenomena during treatment with vedolizumab
D. Lissner et al.
Journal of Crohns & Colitis (2017)
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Severine Vermeire et al.
LANCET (2017)
Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
Friederike Fuchs et al.
FRONTIERS IN IMMUNOLOGY (2017)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
Aurelien Amiot et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis
Gaik W. Tew et al.
GASTROENTEROLOGY (2016)
Tu1346 Skin and Joint Side Effects in a Subpopulation of Anti-TNF Experienced IBD Patients, Who Respond to a Treatment With Vedolizumab, a Humanized A4b7 Integrin Antibody
Oliver Drvarov et al.
GASTROENTEROLOGY (2015)
OP022. Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study
Journal of Crohns & Colitis (2015)
OP021. TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC)
Journal of Crohns & Colitis (2015)
Review article: anti-adhesion therapies for inflammatory bowel disease
T. Lobaton et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
IBD and health-related quality of life - Discovering the true impact
Sanna Lonnfors et al.
JOURNAL OF CROHNS & COLITIS (2014)
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire et al.
LANCET (2014)
TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells
Katharina Gerlach et al.
NATURE IMMUNOLOGY (2014)
Cytokines in inflammatory bowel disease
Markus F. Neurath
NATURE REVIEWS IMMUNOLOGY (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease
Luke Jostins et al.
NATURE (2012)
Chemokines and the signaling modules regulating integrin affinity
Alessio Montresor et al.
FRONTIERS IN IMMUNOLOGY (2012)
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
Severine Vermeire et al.
GUT (2011)
CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung
Berber Piet et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
T-cell-directed therapies in inflammatory bowel diseases
Giovanni Monteleone et al.
CLINICAL SCIENCE (2010)
Intestinal inflammation abrogates the tolerogenic properties of MLN CD103+ dendritic cells
Sophie Laffont et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Role of β7 Integrins in Intestinal Lymphocyte Homing and Retention
G. Gorfu et al.
CURRENT MOLECULAR MEDICINE (2009)
Targeted Therapies in Inflammatory Bowel Disease
Britta Siegmund
DIGESTIVE DISEASES (2009)
Clinical aspects of inflammatory bowel disease
Britta Siegmund et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Mucosal T cell proliferation and apoptosis in inflammatory bowel disease
Andreas Sturm et al.
CURRENT DRUG TARGETS (2008)
Homing imprinting and immunomodulation in the gut: Role of dendritic cells and retinoids
J. Rodrigo Mora
INFLAMMATORY BOWEL DISEASES (2008)
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β- and retinoic acid-dependent mechanism
Janine L. Coombes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2007)
Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells
Frederick Masson et al.
JOURNAL OF IMMUNOLOGY (2007)
Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE trial
Stephan R. Targan et al.
GASTROENTEROLOGY (2007)
Getting to the site of inflammation: the leukocyte adhesion cascade updated
Klaus Ley et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Essential role for CD103 in the T cell-mediated regulation of experimental colitis
O Annacker et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics
SK Bromley et al.
NATURE IMMUNOLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Retinoic acid imprints gut-homing specificity on T cells
M Iwata et al.
IMMUNITY (2004)
Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells
JR Mora et al.
NATURE (2003)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists
S Mandala et al.
SCIENCE (2002)
JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes
G Ostermann et al.
NATURE IMMUNOLOGY (2002)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
Advances in immunology: T-cell function and migration - Two sides of the same coin
UH von Andrian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
